Health & Fitness
Fri, April 6, 2012Thu, April 5, 2012Wed, April 4, 2012Tue, April 3, 2012Mon, April 2, 2012Sun, April 1, 2012Sat, March 31, 2012Fri, March 30, 2012Thu, March 29, 2012Wed, March 28, 2012Tue, March 27, 2012Mon, March 26, 2012Sun, March 25, 2012Sat, March 24, 2012Fri, March 23, 2012Thu, March 22, 2012Unigene to Present at the 11th Annual Needham Healthcare Conference
//health-fitness.news-articles.net/content/2012/ .. e-11th-annual-needham-healthcare-conference.html
Published in Health and Fitness on Thursday, March 29th 2012 at 6:17 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Unigene to Present at the 11th Annual Needham Healthcare Conference -- BOONTON, N.J., March 29, 2012 /PRNewswire/ --
Unigene to Present at the 11th Annual Needham Healthcare Conference
BOONTON, N.J., March 29, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that David Moskowitz, Chief Financial Officer, will present a corporate overview at the 11th Annual Needham Healthcare Conference 2012 in New York, NY. Mr. Moskowtiz's presentation is scheduled to begin at 2:40 p.m. ET on Wednesday, April 4, 2012.
A live webcast of the presentation will be available by visiting the Investors and Media section under the Events tab of the Unigene web site, [ http://www.unigene.com ]. Participants should allow 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]
Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[ jrando@tiberend.com ] / [ amielach@tiberend.com ]
SOURCE Unigene Laboratories, Inc.
[ Back to top ] RELATED LINKS
[ http://www.unigene.com ]
